Loading
NASDAQHealthcareBiotechnology
Latest quote
$138.77
+$7.43 · +5.66%
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Previous close
$138.77
+$7.43 · +5.66%
Regular session · ET · Market data may be delayed.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Day range
Current $138.77
52-week range
Current $138.77
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
25
Expensive
Sentiment
61
Bullish
Risk
40
Moderate Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Day range
Current $138.77
52-week range
Current $138.77
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI59.37M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI48.23M0.49%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM41.23M0.05%78.74B USD0.19%$278.94+0.49%
iShares Russell 2000 Growth ETFIWO14.42M0.10%13.92B USD0.24%$356.78+0.94%
Vanguard Russell 2000 ETFVTWO9.63M0.05%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA8.52M0.04%21.82B USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT4.84M0.02%22B USD0.09%$319.01+1.64%
Vanguard U.S. Momentum Factor ETFVFMO3.51M0.18%1.9B USD0.13%$230.11+1.02%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTVanguard U.S. Momentum Factor ETFVFMOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
